Individualized ASO
Phase 2Small molecule
Individualized ASO is one of 7 small molecule programs targeting Central Nervous System. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Central Nervous System
#DrugCompanyPhaseTrials
1Imuran
LLegacy Health System
Phase 3
Furmonertinib
AAllist Pharmaceuticals, Inc.
Phase 2
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Salbutamol
GSKPreclinical
Individualized ASO
EEveryONE Medicines Inc.
Phase 2
Endotoxin
UUniversity of California, Los Angeles
Preclinical
TNF Alpha
CChung Shan Medical University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Individualized ASO. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEveryONE Medicines Inc.